Xencor
Develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€982m (Public information from Sep 2024)
Share price
$21.2 XNCR
Monrovia California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 123m | 275m | 165m | 168m | 68.5m | 116m | 180m |
| % growth | (22 %) | 124 % | (40 %) | 2 % | (59 %) | 69 % | 55 % |
| EBITDA | (76.8m) | 43.8m | (82.5m) | (127m) | (246m) | (199m) | (243m) |
| % EBITDA margin | (63 %) | 16 % | (50 %) | (75 %) | (360 %) | (172 %) | (135 %) |
| Profit | (69.3m) | 82.6m | (55.2m) | (126m) | (244m) | (219m) | (184m) |
| % profit margin | (57 %) | 30 % | (34 %) | (75 %) | (357 %) | (189 %) | (102 %) |
| EV / revenue | 15.5x | 7.3x | 5.7x | 3.3x | 8.9x | 9.3x | 6.0x |
| EV / EBITDA | -24.8x | 46.0x | -11.3x | -4.4x | -2.5x | -5.4x | -4.5x |
| R&D budget | 170m | 193m | 200m | 254m | - | - | - |
| R&D % of revenue | 138 % | 70 % | 121 % | 151 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | $123m | Post IPO Equity |
* | N/A | N/A | Post IPO Equity |
* | N/A | $226m | Post IPO Equity |
| N/A | $25.0m | Post IPO Equity | |
* | N/A | $175m | Post IPO Equity |
| Total Funding | €86.3m | ||
Related Content
Recent News about Xencor
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.